X2nSat Selects LeoSat’s Laser-Enabled Data Network to Support Healthcare Communications
6.5.2019 12:20:00 EEST | Business Wire | Press release
LeoSat Enterprises, which is launching a constellation of 108 low-earth-orbit communications satellites that will provide the fastest, most secure and widest coverage data network in the world, today announced that X2nSat, the highly reliable satellite solutions provider, has selected LeoSat to support new infrastructure solutions for the ever-expanding needs of the healthcare industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190506005302/en/
New Satellite Constellation providing the first business backbone in space for Enterprise Data. (Photo: Business Wire)
X2nSat currently offers SatBlue, a proprietary line of voice and data communications solutions tailored for the healthcare industry (including data and internet redundancy, emergency response trailers and telemedicine capabilities), which allows hospitals and medical office buildings to customize communications solutions based on their existing infrastructure, and to expand when the need for additional capabilities arises.
Whether it is through telemedicine, video conferencing or transferring medical records via broadband, hospitals and medical facilities have unique needs when it comes to communications. Network reliability and scalability are key for both service continuity and disaster recovery plans. With healthcare, a back-up communications system not only keeps the business running, it can help save lives.
With data volumes exploding, the increasing demand to move large quantities of data quickly and securely around the world is fast outpacing the infrastructure needed to carry it. LeoSat has developed a unique system architecture – a space-based MPLS network - providing Gigabits of secure connectivity with lower latencies than fiber, opening-up new possibilities for Healthcare providers looking for scalable, flexible solutions for their expanding networks.
Garrett Hill, CEO of X2nSat, said: “Technology is crucial to Healthcare. With cloud computing and Big Data becoming more and more prominent, healthcare providers are seeking a reliable, disaster-resistant backbone for effective healthcare IT management. Satellite is the missing puzzle piece for the delivery of reliable communication and data connectivity. LeoSat’s unique high throughput, low latency and highly secure data communications network will enable us to offer new data and voice connectivity solutions and work closely with healthcare providers to create effective disaster preparedness plans”.
As part of the agreement, Hill receives a designated seat on LeoSat’s Customer Technical Advisory Committee, an institution created to structure collaboration and exchange information surrounding the design, configuration, production, and launch of the LeoSat satellite constellation. Says Hill, “X2nSat’s Las Cruces, New Mexico Satellite Gateway has been designed and optimized for high-throughput satellites, and X2nSat is looking forward to collaborating with LeoSat on how best to deliver the latest generation of solutions to our enterprise customers”.
Michael Abad-Santos, SVP Americas, LeoSat said: “Satellite is often seen as a last resort for enterprise data communications. But with capabilities beyond existing satellite and fiber, including transmission speeds of 5.2 gigabits per second and latency of 20 milliseconds, LeoSat’s infrastructure is what data communications has been waiting for – a game-changing service which realizes the synergies of both worlds to re-define connectivity in terms of capacity, latency, security, efficiency and coverage. Using our unique backbone in space we can provide fast and ultra-secure point-to-point data connections to and from anywhere on earth without the need for any terrestrial landings”.
LeoSat is backed by leading satellite operators SKY Perfect JSAT and Hispasat, and the system is being developed in conjunction with Thales Alenia Space, a company with unmatched expertise in designing and manufacturing low earth orbit constellations. The high-throughput satellites (HTS) in the constellation will form a mesh network interconnected through laser links, creating an optical backbone in space which is about 1.5 times faster than terrestrial fiber backbones, thus creating a paradigm shift in the use of satellites for data connectivity – rather than a gap filler or last resort where no terrestrial alternative is available. LeoSat has already secured over 2 Billion USD in pre-launch customer agreements and was recently granted a license by the FCC to operate its network in the U.S. ENDS
NOTE TO EDITORS
To find out more about LeoSat, come along to one of the panels at Sat2019. To arrange an interview, please contact Melanie Dickie. Email: Melanie@leosat.com or call +31 6 14 22 97 62.
- Monday 6 May, 1.30pm: An Introduction to HTS and Other Acronyms (Unveiled Theater)
- Wednesday 8 May, 3pm: Integrating LEO Constellations Into Teleport Services (Room 147)
- Thursday 9 May, 10:45am: Executive Round Table – LEO/MEO Systems (Room 146)
About LeoSat Enterprises
LeoSat Enterprises was established to leverage the latest developments in satellite communications technologies to develop and launch a new low-earth-orbit satellite constellation which will provide the first commercially available, business grade, extremely high-speed and secure data service worldwide. With up to 108 low-earth-orbit communications satellites in the constellation LeoSat is the first company to have all the High Throughput Satellites (HTS) in the constellation interconnected through laser links, creating an optical backbone in space which is about 1.5 times faster than terrestrial fiber backbones and without the need for any terrestrial touchpoints. This unique set of features enables LeoSat to provide instant infrastructure from anywhere to everywhere which is fast, secure and reliable.
Based in Washington DC, LeoSat is currently working with Thales Alenia Space for the low-earth-orbit constellation of Ka-band communications satellites. Once operational, the constellation will provide high-speed, low-latency and highly secure communications and bandwidth for business operations in the telecom backhaul, Energy, Maritime, Government and international business markets. Launch of the constellation is expected in 2020. www.leosat.com
About X2nSat
Founded in 1996, X2nSat provides highly reliable wireless network and communications solutions, with a commitment to making the world, business and life better with reliable communication anytime, anywhere. Working “above the cloud,” X2nSat offers the robust services of a large telecommunications company with the personalized customer care of a specialty organization, and is a leading provider of satellite technology to enterprise organizations in healthcare, utilities, and other industries. For more information, visit www.X2nSat.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190506005302/en/
Contact information
Melanie Dickie
VP Marketing & Communications, LeoSat Enterprises
Tel:
+31 6 14 22 97 62
Email: melanie@leosat.com
Media
Contact for X2nSat:
Jena Blazer, Director of Sales and Marketing
+1.707.664.5712
jena.blazer@x2nsat.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 12:52:00 EEST | Press release
The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not merely a wage dispute. It stems from deep structural concerns regarding the company’s ESG management, lack of operational autonomy, and passive labor relations. Primarily, the union highlighted unresolved corporate governance issues, including allegations concerning unfair labor practices and the unauthorized use of employee personal data, which were prominently reported by South Korea's major broadcaster, MBC, in November 2025. The union believes this crisis stems from management's failure to address r
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 12:00:00 EEST | Press release
The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that elevates high-performance riders and horses to their rightful place on the world stage. Built on merit, integrity, and excellence, the PJL brings together the world’s best athletes to compete for the biggest prize pot in the discipline’s history, helping to create a more resilient, long-term financial model for the sport. Represented by sixteen teams, the PJL will introduce an industry-first rider selection process from a pool of 250 of the world’s leading riders. World-class, immersive events will unfold across fourteen ic
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 12:00:00 EEST | Press release
Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkbj) for the treatment of spastic cerebral palsy (CP). On top of safety and tolerability, the study will evaluate improvements in daily functioning, quality of life, motor abilities, and neurodevelopmental measures of the Cenegermin-bkbj intranasal formulation. CP is the most common motor disability in childhood, caused by injury or changes during early brain development. The most prevalent form, spastic CP, leads to muscle stiffness and difficulty with movement.2 “Cerebral palsy is a devastating disease, and for patients and families there are still no proven treatments beyond supportive care,” said Marcello Allegretti, Chief Scientific Officer at Dompé. “With our emerging intranasal NGF p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
